Estrogen Patch Shortage Continues as Manufacturers Cite Federal Policy-Driven Demand Spike
Pharmaceutical manufacturers report ongoing supply shortages of estrogen patches in the U.S., attributing the shortage to increased demand following federal policy changes implemented earlier in 2026. The manufacturers flagged supply issues earlier this year but federal regulators have not yet officially recognized a shortage. The continued supply constraints affect Medicaid beneficiaries' access to hormone replacement therapy, potentially forcing plans and providers to manage formulary alternatives and prior authorization processes for affected members seeking this form of estrogen therapy.
Medicaid managed care plans may face increased prior authorization requests and member appeals as providers seek coverage for alternative estrogen formulations while patches remain unavailable.
Pharmacy · Managed Care
You might also like